The quest to overcome resistance to EGFR-targeted therapies in cancer
- PMID: 24202392
- PMCID: PMC4049336
- DOI: 10.1038/nm.3388
The quest to overcome resistance to EGFR-targeted therapies in cancer
Abstract
All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually develop resistance. An increasing understanding of the number and complexity of resistance mechanisms highlights the Herculean challenge of killing tumors that are resistant to EGFR inhibitors. Our growing knowledge of resistance pathways provides an opportunity to develop new mechanism-based inhibitors and combination therapies to prevent or overcome therapeutic resistance in tumors. We present a comprehensive review of resistance pathways to EGFR-targeted therapies in lung, colorectal and head and neck cancers and discuss therapeutic strategies that are designed to circumvent resistance.
Conflict of interest statement
The authors declare competing financial interests: details are available in the online version of the paper.
Figures
Similar articles
-
Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.Int J Mol Sci. 2017 Nov 15;18(11):2420. doi: 10.3390/ijms18112420. Int J Mol Sci. 2017. PMID: 29140271 Free PMC article. Review.
-
Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer.Mol Cancer Ther. 2017 Feb;16(2):265-272. doi: 10.1158/1535-7163.MCT-16-0105. Mol Cancer Ther. 2017. PMID: 28159915 Review.
-
Mechanisms of resistance to EGFR targeted therapies.Cancer Biol Ther. 2013 Apr;14(4):304-14. doi: 10.4161/cbt.23627. Epub 2013 Jan 28. Cancer Biol Ther. 2013. PMID: 23358468 Free PMC article. Review.
-
Therapeutic targeting of the epidermal growth factor receptor in human cancer.Crit Rev Oncog. 2012;17(1):31-50. doi: 10.1615/critrevoncog.v17.i1.40. Crit Rev Oncog. 2012. PMID: 22471663 Review.
-
Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.Clin Cancer Res. 2014 Dec 1;20(23):5898-907. doi: 10.1158/1078-0432.CCR-13-2437. Epub 2014 Oct 10. Clin Cancer Res. 2014. PMID: 25303979 Free PMC article. Review.
Cited by
-
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?Cell Commun Signal. 2024 Oct 11;22(1):489. doi: 10.1186/s12964-024-01876-4. Cell Commun Signal. 2024. PMID: 39394159 Review.
-
Pan-cancer Comprehensive Analysis Identified EGFR as a Potential Biomarker for Multiple Tumor Types.Appl Biochem Biotechnol. 2024 Oct 1. doi: 10.1007/s12010-024-05060-9. Online ahead of print. Appl Biochem Biotechnol. 2024. PMID: 39352450
-
Discovery of potent allosteric antibodies inhibiting EGFR.MAbs. 2024 Jan-Dec;16(1):2406548. doi: 10.1080/19420862.2024.2406548. Epub 2024 Sep 20. MAbs. 2024. PMID: 39304998 Free PMC article.
-
Versatile Split-and-Mix Liposome PROTAC Platform for Efficient Degradation of Target Protein In Vivo.JACS Au. 2024 Jul 11;4(8):2915-2924. doi: 10.1021/jacsau.4c00278. eCollection 2024 Aug 26. JACS Au. 2024. PMID: 39211615 Free PMC article.
-
Discovering the effect of combination of celecoxib and sorafenib on hepatocellular carcinoma.Discov Oncol. 2024 Jul 31;15(1):321. doi: 10.1007/s12672-024-01203-w. Discov Oncol. 2024. PMID: 39083127 Free PMC article.
References
-
- Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011;364:947–955. - PubMed
-
- Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160–1174. - PubMed
-
- Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010;277:301–308. - PubMed
-
- Weinstein IB. Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science. 2002;297:63–64. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous